AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline
UNITED STATES, JUN 30 – AbbVie will pay up to $2.1 billion to acquire Capstan's in vivo CAR-T platform and lead candidate CPTX2309, advancing scalable treatments for B cell-driven autoimmune diseases.
- On June 30, 2025, AbbVie announced a definitive agreement to acquire Capstan Therapeutics, including its lead program CPTX2309 and proprietary tLNP platform.
- AbbVie sought to expand its immunology pipeline as Humira faces biosimilar competition and Capstan develops novel in vivo CAR-T therapies for autoimmune diseases.
- CPTX2309 delivers mRNA via lipid nanoparticles to reprogram T cells to deplete pathogenic B cells without lymphodepletion, with a Phase 1 trial enrolling healthy volunteers underway.
- AbbVie will provide up to $2.1 billion in cash upfront as part of the acquisition, and company leadership highlighted that initial Phase 1 results demonstrate rapid and substantial B-cell depletion, supporting the clinical potential of CPTX2309.
- The acquisition positions AbbVie to develop scalable, disease-modifying immunology therapies with in vivo cell engineering, potentially reshaping autoimmune disease treatment.
20 Articles
20 Articles
In Vivo CAR T Cell Generation For Cancer And Auto-Immune Treatments
With immunotherapy increasingly making it out of the lab and into hospitals as a viable way to treat serious conditions like cancer, there’s a lot of pressure to optimize these therapies. This is especially true for therapies involving chimeric antigen receptor (CAR) T cells, which so far required a cumbersome process of extracting the patient’s T cells, modifying them ex vivo and returning the now CAR T cells to the patient’s body. After a rece…
MedCity News
DealbreakerAbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline
AbbVie is acquiring Capstan Therapeutics, a startup with technology that enables in vivo engineering of immune cells. The University of Pennsylvania spinout’s lead program recently began a Phase 1 test as a potential treatment for B cell-mediated autoimmune disorders. The post AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline appeared first on MedCity News.
AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
/PRNewswire/ -- AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. ("Capstan"), a clinical-stage biotechnology company dedicated to advancing in vivo...
AbbVie to Buy Capstan for up to $2.1 Billion in Immunology Push
Coverage Details
Bias Distribution
- 89% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
